Doctors, Immune Response and In-Vivo - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Doctors

Immune Response

In-Vivo

Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target

The Pharma Data

JANUARY 4, 2021

Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses. Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells.

In-Vivo

In-Vivo Development Immune Response Big Data

Necessity Is the Mother of Innovation: Key Trends and Predictions from Biotech Showcase Digital After an Unprecedented Year That Drove Momentous Changes in Healthcare

Pharma Marketing Network

JANUARY 20, 2021

It’s widely acknowledged that optimal vaccine immunity results from engaging both humoral and cellular responses, but less attention has been given to the role of mucosal immunity in protecting against COVID-19, which is surprising considering SARS-CoV-2 enters the human body primarily through the mucosal surfaces of the upper respiratory tract.

Vaccination

Vaccination Vaccine In-Vivo Genetics

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target

Necessity Is the Mother of Innovation: Key Trends and Predictions from Biotech Showcase Digital After an Unprecedented Year That Drove Momentous Changes in Healthcare

Webinars

Stay Connected